In the PDAC cohort, the ORR was 33.3% with a median PFS of 5.4 months.380 Previous data reported from other cohorts of this trial already demonstrated clinical activity and tolerability of adagrasib in previously treated patients with KRAS-G12C CRC. Here, KRAS is linked to colorectal carcinoma.